NCT05469009: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
- State
- Under way
- Phase
- Early Phase 1
- People
- 15 planned
- Started
- 14 Jul 2022
- Primary completion
- Jul 2029
- Arms
- Infusion plus Exablate BBBO Treatment
- Results
- None posted
- 14 Jul 2022: Trial started
- 21 Jul 2022: Trial registered